Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06982820 · ClinicalTrials.gov registry record · NA
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
A NA study of Depressive Disorder, Major, sponsored by GrayMatters Health.
- Recruiting
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 3
- Study locations
NCT06982820: Recruiting NA study of Depressive Disorder, Major, sponsored by GrayMatters Health.
NCT06982820 is a NA study of Depressive Disorder, Major that is actively recruiting participants, run by GrayMatters Health. The registered enrollment target is 170 participants, below the 239-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (29% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06982820, a NA study of Depressive Disorder, Major, is actively recruiting participants, sponsored by GrayMatters Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).
Primary Outcome
Hamilton Rating Scale for Depression - the maximum score is 64. A score above 20 is considered a severe depression.
Conditions Studied
Interventions
- DEVICE Prism Training
Study Locations (3)
Rhode Island
- Butler Hospital - Providence
Texas
- Houston Center For Advanced Psychiatric Treatment - Houston
Other
- Sheba Medical Center - Ramat Gan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2027-08-30 |
| Phase | NA |
What NCT06982820 shows while recruiting
NCT06982820 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 239-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which Prism Training is the first listed.
NCT06982820 reports a single indexed study location in Rhode Island, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06982820 about?
NCT06982820 is a clinical study titled "Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia". The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of ne...
What is the current status of trial NCT06982820?
This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2025-06-25. Estimated completion is 2027-08-30.
What conditions does trial NCT06982820 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT06982820?
The interventions under investigation include: Prism Training (DEVICE).
Who is sponsoring clinical trial NCT06982820?
This trial is sponsored by GrayMatters Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06982820 being conducted?
This trial has 3 study locations across Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06982820's enrollment target sits among peer trials
170 24th of 52 higher than 29 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
RECRUITING · NA
-
Biomarkers of Depression and Treatment Response
RECRUITING · NA
-
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
ACTIVE NOT RECRUITING · NA
-
In-person vs. Remote Wellness Support
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI